Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;5(1):73-80.
doi: 10.1177/1758834012463260.

New treatment approaches in melanoma: current research and clinical prospects

Milap G Rughani  1 , Avinash Gupta, Mark R Middleton
Affiliations

New treatment approaches in melanoma: current research and clinical prospects

Milap G Rughani et al. Ther Adv Med Oncol. 2013 Jan.

Abstract

Ipilimumab and vemurafenib have changed the clinical landscape in melanoma. Both drugs offer effective treatment for metastatic melanoma, but with limitations. Ipilimumab benefits only a minority of those treated, with no means to identify them prospectively. The efficacy of vemurafenib is tied to the presence of an activating mutation in BRAF, and so is more predictable. However, acquired resistance develops within months. As we understand these, and similar, agents better, the means to select patients for treatment, to increase the duration of response and to identify the best stage at which to intervene will lead to improved outcomes for patients. Several trials are already under way or being developed to build upon these exciting discoveries.

Keywords: clinical management; immunotherapy; melanoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Mark R. Middleton has received research funding and honoraria from Astrazeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck and Roche, whose drugs are featured in this.

References

    1. Ascierto P., Marincola F., Ribas A. (2011) Anti-Ctla4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 9: 196. - PMC - PubMed
    1. Ascierto, et al. (2012) Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 30: (suppl; abstr. 8511).
    1. Ashida A., Takata M., Murata H., Kido K., Saida T. (2009) Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 124: 862–868 - PubMed
    1. Atkins M., Kunkel L., Sznol M., Rosenberg S. (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl. 1): S11–S14 - PubMed
    1. Atkins M., Middleton M., Chapman P. (2009) Chemotherapy-based treatment of metastatic melanoma. In: Atkins M. (ed.), Cutaneous Melanoma, 5th edn. St. Louis, MO: Quality Medical Publishing, Inc.